Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Fowler Website

Daniel H. Fowler, M.D.

Selected Publications

1)  Felizardo TC, Foley J, Steed K, Dropulic B, Amarnath S, Medin JA, Fowler DH.
Harnessing autophagy for cell fate control gene therapy.
Autophagy. 9: 1069-79, 2013.
[Journal]
2)  Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A, Kreitman RJ, Miettinen MM, Steinberg SM, Fowler DH, Pastan I.
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression.
Sci Transl Med. 5: 208ra147, 2013.
[Journal]
3)  Castiello L, Mossoba M, Viterbo A, Sabatino M, Fellowes V, Foley JE, Winterton M, Halverson DC, Civini S, Jin P, Fowler DH, Stroncek DF.
Differential gene expression profile of first-generation and second-generation rapamycin-resistant allogeneic T cells.
Cytotherapy. 15: 598-609, 2013.
[Journal]
4)  Baird K, Steinberg SM, Grkovic L, Pulanic D, Cowen EW, Mitchell SA, Williams KM, Datiles MB, Bishop R, Bassim CW, Mays JW, Edwards D, Cole K, Avila DN, Taylor T, Urban A, Joe GO, Comis LE, Berger A, Stratton P, Zhang D, Shelhamer JH, Gea-Banacloche JC, Sportes C, Fowler DH, Gress RE, Pavletic SZ.
National Institutes of Health Chronic Graft-versus-Host Disease Staging in Severely Affected Patients: Organ and Global Scoring Correlate with Established Indicators of Disease Severity and Prognosis.
Biol. Blood Marrow Transplant. 19: 632-9, 2013.
[Journal]
5)  Foglietta M, Neelapu SS, Kwak LW, Jiang Y, Nattamai D, Lee ST, Fowler DH, Sportes C, Gress RE, Steinberg SM, Vence LM, Radvanyi L, Dwyer KC, Qazilbash MH, Bryant RN, Bishop MR.
Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients.
Bone Marrow Transplant. 48: 269-77, 2013.
[Journal]
6)  Fowler DH, Mossoba ME, Steinberg SM, Halverson DC, Stroncek D, Khuu HM, Hakim FT, Castiello L, Sabatino M, Leitman SF, Mariotti J, Gea-Banacloche JC, Sportes C, Hardy NM, Hickstein DD, Pavletic SZ, Rowley S, Goy A, Donato M, Korngold R, Pecora A, Levine BL, June CH, Gress RE, Bishop MR.
Phase II clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation.
Blood. [Epub ahead of print], 2013.
[Journal]
7)  Pavletic SZ, Fowler DH.
Are we making progress in GVHD prophylaxis and treatment?.
Hematology Am Soc Hematol Educ Program. 2012: 251-64, 2012.
[Journal]
8)  Neschadim A, Wang JC, Sato T, Fowler DH, Lavie A, Medin JA.
Cell fate control gene therapy based on engineered variants of human deoxycytidine kinase.
Mol. Ther. 20: 1002-13, 2012.
[Journal]
9)  Grkovic L, Baird K, Steinberg SM, Williams KM, Pulanic D, Cowen EW, Mitchell SA, Hakim FT, Martires KJ, Avila DN, Taylor TN, Salit RB, Rowley SD, Zhang D, Fowler DH, Bishop MR, Gress RE, Pavletic SZ.
Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity.
Leukemia. 26: 633-43, 2012.
[Journal]
10)  Hardy NM, Fellowes V, Rose JJ, Odom J, Pittaluga S, Steinberg SM, Blacklock-Schuver B, Avila DN, Memon S, Kurlander RJ, Khuu HM, Stetler-Stevenson M, Mena E, Dwyer AJ, Levine BL, June CH, Reshef R, Vonderheide RH, Gress RE, Fowler DH, Hakim FT, Bishop MR.
Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation.
Blood. 119: 2956-9, 2012.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 11/21/2013.